Results: We identified 15 kindreds with CARD14-associated papulosquamous eruption (CAPE). Characteristic features of CAPE include early age of onset; prominent involvement of the cheeks, chin, and ears; family history of psoriasis or PRP; minimal response to conventional topical and systemic psoriasis therapies; and improvement with ustekinumab.
Limitations: Relatively small sample size.
Conclusions: Many subjects with CARD14 mutations display characteristics of both psoriasis and PRP. We propose the term CARD14-associated papulosquamous eruption to describe this spectrum of disease. Subjects with clinical features suggestive of CAPE should undergo CARD14 sequencing and may benefit from treatment with ustekinumab. ( J Am Acad Dermatol 2018;79:487-94.)
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Psoriasis and pityriasis rubra pilaris (PRP) have traditionally been considered distinct entities with overlapping therapeutic choices. Heterozygosity for mutation in caspase recruitment domain family member 14 gene (CARD14) (MIM 697211), which encodes caspase recruitment domain family member 14, 1 has been independently reported to be associated with familial and nonfamilial forms of psoriasis, including pustular psoriasis and psoriasis associated with arthritis, 2,3 as well as with familial PRP, 4 indicating that these disorders share a common underlying pathophysiology. We describe 15 families with mutations in CARD14, members of which display a range of clinical findings that include features of both psoriasis and PRP. We propose the term CARD14-associated papulosquamous eruption (CAPE) to describe this spectrum of disease. We include the first observation of homozygosity for a pathogenic CARD14 mutation in a subject with a severe phenotype and describe 6 subjects who responded favorably to treatment with ustekinumab after failure to respond to other therapies.
METHODS
The study was approved by the Yale Human Investigational Committee and complies with the Declaration of Helsinki principles. Subjects were referred by dermatologists from a variety of institutions for participation in a genetic study of inherited disorders of keratinization, many with a suspected diagnosis of PRP. Individual consent or parental permission was obtained in writing for each case. DNA was isolated from peripheral blood or saliva of the index case in each kindred, and either exome sequencing, GeneRead targeted sequencing, or Sanger sequencing was performed as previously described. 5 The medical records of subjects demonstrating CARD14 mutations were reviewed.
RESULTS
A total of 15 kindreds with CARD14 mutations were identified, and clinical features of the index cases are presented in detail in Table I . With the exception of 2 subjects, all had onset of their disease at or before 1 year of age. The skin phenotype ranged from predominantly psoriasis-like to predominantly PRP-like, with several subjects showing features typical of both diseases. Two subjects were erythrodermic. The most notable characteristic among the group was prominent facial involvement, which was displayed by all subjects but 1 and in most cases presented early in the disease course as symmetric, well-demarcated pink-red patches or thin plaques involving the bilateral cheeks and chin with sparing of the infralabial region (Fig 1) . Many subjects also had erythema of the ears. Involvement of the trunk and extremities was more variable, ranging from scattered pink, scaly plaques to confluent erythema and scale (Fig 2, A-D) . One subject showed striking patterned plaques on the chest and back
CAPSULE SUMMARY d
Caspase recruitment domain family member 14 gene (CARD14) mutations have been associated with psoriasis and familial pityriasis rubra pilaris. Characteristic features of subjects with CARD14 mutations include early onset, prominent facial involvement, and favorable response to ustekinumab therapy. Subjects with suggestive clinical findings should undergo genetic testing, given the high probability of response to ustekinumab if CARD14 mutations are found. (Fig 2, C ) , and 2 subjects did not have any truncal involvement. Five subjects displayed classic ''islands of sparing,'' and 6 showed follicular papules that are typical of PRP. Most subjects (12 of 15) had some degree of palmoplantar keratoderma, and 2 had scleroderma-like changes of the hands.
The subjects have been treated with a number of modalities with varying degrees of success. None has experienced remission of disease without treatment. Response to topical medications, including corticosteroids, calcineurin inhibitors, Vitamin D analogues, topical retinoids, and tar preparations had been universally minimal among the group. Responses to other treatments, including phototherapy, oral retinoids, methotrexate, cyclosporine, and biologic therapies had been variable and are detailed in Table I . Among the 8 subjects who had been treated with etanercept as monotherapy, only 1 demonstrated partial response, 6 had minimal response, and 1 had worsening. Notable is the near-complete response to ustekinumab in 5 of 6 subjects treated and partial response in the sixth (subject 5), who had the most severe phenotype and was also notably the heaviest and thus may have required a higher dosage. Indeed, subject 9 required 90 mg (1.2 mg/kg) dosed every 8 weeks to maintain near-complete clearance (Fig 3) . He has recently been transitioned to guselkumab in the hope that it might yield similar improvement but at the standard dosing regimen. Doses for the other subjects treated with ustekinumab range from 0.7 mg/kg (in addition to methotrexate) to 1.1 mg/kg every 12 weeks.
DISCUSSION
CARD14 mutations are independently associated with psoriasis 2,3 and familial PRP, 4 providing a pathophysiologic link between these disorders. The subjects in this series provide striking clinical evidence for this connection and display findings characteristic of both PRP and psoriasis. Although all of the subjects have some features consistent with PRP, their presentations do not fit squarely within the traditional PRP classification. 6 The early age of onset and chronicity of disease are consistent with atypical juvenile PRP, but many subjects do not display the typical keratotic papules and only 2 show scleroderma-like changes of the hands. In addition, a few subjects demonstrate the typical islands of sparing characteristic of classic adult and juvenile PRP, but others show generalized scaly plaques that are more reminiscent of extensive plaque psoriasis. Three subjects have arthritis, which is reported in approximately 5% to 30% of subjects with psoriasis [7] [8] [9] but is uncommonly associated with PRP. 10, 11 These varying phenotypes support the requirement for other environmental and genetic factors beyond the CARD14 mutation in determining clinical manifestations and disease severity.
With the exception of p.Q157P, all of the CARD14 mutations in our subjects have either been previously reported or change the same nucleotide as previously reported mutations.
3,4,12-16 Repeated occurrence of mutations at a small number of clustered sites in unrelated families, many of which arose de novo, provides further evidence of the critical importance of these specific residues to CARD14 function and pathobiology. Notably, we report what to our knowledge is the first observation of homozygosity for a rare pathologic mutation in CARD14. Although this subject's phenotype is more severe than that of her heterozygous relatives, it is not the most severe in our cohort, nor are any unique features apparent. This suggests that there is relatively little dosage effect for the p.G117S mutation.
CARD14 functions as an activator of nuclear factor k light-chain enhancer of activated B cells (NF-kB) signaling, 1, 17 and NF-kB has been shown to be up-regulated in the skin of subjects with PRP and CARD14 mutations. 4 Elevated NF-kB activity leads to increases in chemokines such as interleukin 8 (IL-8) and C-C motif chemokine ligand 20, which lead to recruitment and differentiation of inflammatory cells, including production of IL-23 by dendritic cells and IL-17 and IL-22 by T cells. 3 As an inhibitor that targets both IL-12 and IL-23 cytokines by binding to their shared p40 subunit, 18, 19 ustekinumab is a pathogenesis-based treatment for CAPE, as demonstrated by the marked clinical response in 5 of 6 subjects treated with ustekinumab in our series. Given the weight of the sixth subject, we speculate that he might have demonstrated greater improvement had he received a higher dose, as 20 and others in this series received higher doses and/or more frequent administration. PRP is often difficult to treat, but ustekinumab has also been used successfully to treat adult-onset PRP in several case reports [21] [22] [23] [24] [25] [26] and recently in 2 subjects with familial PRP associated with CARD14 mutation. 12, 16 Guselkumab, which is an IL-23p19 inhibitor recently approved for the treatment of plaque psoriasis, represents another potential pathogenesis-based treatment for this group of subjects, as do secukinumab (an IL-17A inhibitor) and ixekizumab (an IL-17 inhibitor). Notably, however, the 1 subject in this series treated with ixekizumab had only a partial response.
The possibility of CARD14 mutation should be considered in subjects with papulosquamous eruptions characterized by features of both psoriasis and PRP, especially those who present MTX, methotrexate; NBUVB, narrowband ultraviolet B; PPK, palmoplantar keratoderma; PUVA, psoralen with ultraviolet A; q8w, every 9 weeks; q12w, every 12 weeks.
*DNA of family member sequenced and shares mutation.
y DNA of family member not evaluated. with early onset of disease, facial involvement, and family history of psoriasis or PRP. Although individually these characteristics are not specific, the constellation of findings is highly suggestive of CAPE, particularly when coupled with inadequate response to conventional psoriasis therapies such as methotrexate, acitretin, or tumor necrosis factor-a inhibitors. Our experience positions ustekinumab as the preferred treatment for this group of subjects; however, higher than standard dosing and/or more frequent dosing may be necessary to maintain improvement. On the basis of the pathogenesis of CAPE, guselkumab, secukinumab and ixekizumab may also be effective and therefore warrant further exploration. Although we expect that over time we will learn more about the range of clinical features associated with CAPE, we hope that our experience with this group of subjects will help to identify and successfully treat affected individuals.
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